ELC Group Expands into Pharmaceutical Product Development Market
News Jun 13, 2015
ELC Group has announced that it is expanding into the pharmaceutical development market with the creation of an extensive product portfolio targeting a range of therapeutic areas.
The products, currently under development by an ELC Group specialist team at R&D laboratories will be marketed across the US, EU, LATAM, MENA and China. ELC Group estimates that the complete portfolio will generate an estimated value of 2 Billion USD in annual sales after initial launch. ELC Group intends to sign key strategic global partners for licensing and distribution.
The new product portfolio will address a range of therapeutic areas, including oncology, cardiovascular treatment, diabetes and pain management and ophthalmic solutions. The product set is being developed using the very latest techniques, including advanced technologies such as liposome systems and soft gel.
ELC Group selected the products based on a number of key criteria, including global market size, annual drug sales, prior experience, expertise, and therapeutic categories. Some of the products are being developed with very specific IP considerations and will qualify as Paragraph IV filings in the US, 505 b2 applications in the US, Hybrid applications in the EU, and first generics.
Commenting on the new product portfolio development, ELC Group CEO Marco Rubinstein said: “Our rapid growth, built on intense demand from our global customers, has meant that our business has been naturally moving towards this solution expansion for some time. We have some of the world’s leading experts working on the development of these products and we are keenly anticipating bringing them successfully to market in the near future.”
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Medherant Expands Team with Appointment of David Davies as Head of DevelopmentNews
Medherant Ltd, a leader in next-generation transdermal drug delivery, is pleased to announce the appointment of a new senior executive, David Davies, as Head of Development.READ MORE
Empowering Women in Technology Key to Boosting UK EconomyNews
A new report launched at London Stock Exchange for International Women’s Day, reveals the critical role women play in driving economic growth across the UK, with detailed research on 1,279 women-led companies showing a total contribution of £25.9 billion in revenue to the UK economy.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018